Oxford Bioscience Partners
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance
Business Model:
Revenue: $15.3M
Employees: 2-10
Rankings
Detailed Oxford Bioscience Partners Information
Geographic Data
Address: 12 Giles Place
City: Mansfield
State: MA
Zip: 02048
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. While willing to consider an investment in a company at almost any stage, OBP primarily works with early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide.
Contact Phone:
+16173577474
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2005 | FlowMedica | Series D | 0 |
| 5/2007 | Intechra Holdings | Series C | 0 |
| 1/2004 | Accelerated Technologies | Series B | 32M |
| 3/2005 | Alantos Pharmaceuticals | Series B | 0 |
| 10/2000 | Hypnion | Series A | 10.4M |
| 6/2009 | VaxInnate | Series D | 30M |
| 3/2010 | Seahorse Bioscience | Series D | 5M |
| 5/2012 | Mitralign | Series D | 0 |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 2/2005 | Cambrios Technologies | Series B | 12M |
| 8/2004 | Cambrios Technologies | Series A | 1.8M |
| 4/2007 | Cambrios Technologies | Series C | 18.5M |
| 11/2009 | Cambrios Technologies | Series D | 14.5M |
| 5/2004 | Ensemble Discovery | Series A | 15M |
| 11/2007 | Ensemble Discovery | Series B | 15M |
| 4/2003 | Sirna Therapeutics | Venture Round | 48M |
| 1/2000 | CardioFocus | Series B | 0 |
| 11/2006 | Pathway Medical Technologies | Series B | 25M |
| 7/2002 | Scion Pharmaceuticals | Series B | 0 |
| 12/2007 | Mitralign | Series C | 0 |
| 2/1998 | Agromed | Venture Round | 8.2M |
| 6/2006 | Melinta Therapeutics | Series C | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 9/2004 | Solexa | Series B | 0 |
| 3/2003 | Acadia Pharmaceuticals Inc. | Series F | 25M |
| 5/2002 | ImpactRx | Series C | - |
| 1/2010 | ImpactRx | Series E | 0 |
| 11/2008 | Molecular Biometrics | Series A | 12M |
| 8/2007 | BioProcessors | Series C | 10M |
| 6/2002 | Zone Labs | Series C | 0 |
| 1/2004 | ZettaCore | Series B | 17.5M |
| 10/2009 | Coherex Medical | Series B | 16.5M |
| 8/2004 | Enanta Pharmaceuticals | Venture Round | 20M |
| 5/2001 | Zone Labs | Series B | 0 |
| 7/2003 | Cohesive Technologies | Series B | 9.5M |
| 1/2001 | Percutaneous Valve Technologies (PVT) | Series A | 5.5M |
| 10/2007 | Luca Technologies | Series B | 20M |
| 4/2007 | Radius Health | Series B | 57.5M |
| 1/2002 | Melinta Therapeutics | Series A | 22M |
| 4/2007 | Nfocus Neuromedical | Series B | 20.3M |
| 8/2001 | CardioFocus | Series C | 0 |
| 1/2010 | Molecular Biometrics | Series B | 12.5M |
| 1/1999 | Message Pharmaceuticals | Venture Round | 6.3M |
| 9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
| 3/2003 | Catalyst Bioscience | Venture Round | 60M |
| 7/2005 | Solstice Neurosciences | Venture Round | 8M |
| 1/2003 | SuperDimension | Venture Round | 13M |
| 4/2010 | Adastra Pharmaceuticals | Venture Round | 0 |
| 1/2004 | Enanta Pharmaceuticals | Venture Round | 0 |
| 9/2010 | SuperDimension | Debt | 15M |
| 10/2002 | MicroMed Technology | Series D | 23M |
| 5/2004 | PowderMed | Series A | 35.8M |
| 11/2002 | Dynogen Pharmaceuticals | Series A | 13.3M |
| 1/2007 | Claros Diagnostics | Series A | 0 |
| 11/2001 | Scion Pharmaceuticals | Series A | 4M |
| 7/2002 | Enanta Pharmaceuticals | Series E | 18.3M |
| 1/2008 | Hydrocision | Series H | 4.8M |
| 3/2005 | Pathway Medical Technologies | Series A | 15M |
| 7/2003 | BioProcessors | Series B | 13M |
| 9/2021 | Paperspace | Series F | 0 |
| 4/2001 | NotifyMD | Venture Round | 6.1M |
| 1/2009 | Melinta Therapeutics | Series D | 0 |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 3/2004 | VaxInnate | Series B | 23.1M |
| 10/2006 | VaxInnate | Series C | 40M |
| 1/2008 | Select Laboratory Partners | Series D | 16M |
| 1/2001 | CytoLogix | Series B | 0 |
| 11/2008 | Radius Health | Series C | 15M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 12/2005 | Santhera Pharmaceuticals | Series B | 0 |
| 10/2004 | FlowMedica | Series C | 0 |
| 1/2003 | Impella Cardiosystems | Venture Round | 40M |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 12/2005 | Hypnion | Series B | 0 |
| 11/2006 | Solstice Neurosciences | Series B | 85M |
| 9/2010 | SuperDimension | Equity | 9.8M |
| 7/2000 | Enanta Pharmaceuticals | Series B | 20M |
| 6/2001 | Hydrocision | Series B | 2M |
| 6/2006 | BioProcessors | Series C | 18M |
| 10/2007 | Xencor | Series E | 15M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 3/2009 | Claros Diagnostics | Series B | 0 |
| 11/2003 | Asterand | Series C | 3M |
| 1/2007 | Hydrocision | Series G | 12.7M |
| 3/2000 | Variagenics | Funding Round | 19M |
| 3/2008 | BrainCells | Series B | 30M |
| 1/2003 | Percutaneous Valve Technologies (PVT) | Series B | 14M |
| 9/2004 | Courtagen Life Sciences | Venture Round | 6.6M |
| 7/2003 | Alantos Pharmaceuticals | Series B | 27.7M |
| 1/2007 | CircuLite | Series B | 10.2M |
| 3/2009 | Seahorse Bioscience | Series D | 6M |
| 3/2003 | Hypnion | Series B | 47.5M |
| 5/2008 | ZettaCore | Series C | 15M |
| 11/2007 | Courtagen Life Sciences | Venture Round | 9.5M |
| 7/1999 | Exelixis | Seed Round | 4M |
| 1/2017 | Yolia Health | Series A | 3M |
| 6/2005 | Mitralign | Venture Round | 6.7M |
| 5/2004 | Mitralign | Series A | 0 |
| 7/2005 | BrainCells | Series A | 0 |
| 12/2004 | CircuLite | Series A | 7M |
| 3/2007 | Adastra Pharmaceuticals | Series A | 40M |
| 2/2005 | Acadia Pharmaceuticals Inc. | Post-IPO Equity | 10M |
| 2/2006 | Acadia Pharmaceuticals Inc. | Post-IPO Equity | 20M |
| 7/2003 | Cyberkinetics | Series A | 9.3M |
| 4/2007 | Coherex Medical | Series A | 8.5M |
| 7/2008 | Dicerna Pharmaceuticals | Series A | 8.4M |
| 5/2004 | Ensemble Therapeutics | Series A | 15M |
| 12/2006 | Hydrocision | Series G | 12.7M |
| 5/2014 | CardioFocus | Debt Financing | 0 |
| 2/2002 | BioProcessors | Series A | 6M |
| 1/2012 | Glori Energy | Series C | 0 |
| 2/2006 | Courtagen Life Sciences | Venture Round | 7.6M |
| 2/2011 | CardioFocus | Series C | 0 |
| 12/2003 | Xanthus Pharmaceuticals | Series B | 0 |
| 3/2009 | Pathway Medical Technologies | Series D | 42.5M |
| 3/2007 | Affinium Pharmaceuticals | Series A | 18M |
| 4/2007 | CircuLite | Series B | 5M |
| 1/2010 | CircuLite | Series C | 32.5M |
| 6/2006 | Mitralign | Series B | 13M |
| 12/2008 | Luca Technologies | Series C | 75.9M |
| 9/2021 | Paperspace | Series F | 0 |
| 1/2017 | Yolia Health | Series A | 0 |
| 5/2014 | CardioFocus | Debt Financing | 0 |
| 9/2013 | Affinium Pharmaceuticals | Debt Financing | 0 |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 5/2012 | Mitralign | Series D | 0 |
| 1/2012 | Glori Energy | Series C | 0 |
| 2/2011 | CardioFocus | Series C | 0 |
| 9/2010 | SuperDimension | Venture Round | 0 |
| 9/2010 | SuperDimension | Debt Financing | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
